目的 探讨富马酸伏诺拉生治疗幽门螺杆菌(Hp)阳性消化性溃疡(PU)的临床效果。方法 选取2022-05至2024-04空军军医大学第二附属医院消化内科门诊Hp阳性PU患者94例,随机分为对照组和研究组,每组47例。对照组给予阿莫西林+胶体果胶铋+克拉霉素+奥美拉唑治疗,研究组口服阿莫西林+胶体果胶铋+克拉霉素+富马酸伏诺拉生,治疗2周。比较两组患者溃疡愈合情况、Hp根除情况、临床疗效、胃酸分泌功能及安全性。结果 研究组溃疡愈合率为93.62%(44/47),高于对照组的78.72%(37/47),差异有统计学意义(P＜0.05)。与对照组相比,研究组Hp根除率较高(87.23% vs. 68.09%,P＜0.05)。研究组临床疗效总有效率较高(82.29% vs. 95.74%, χ2=7.029,P＜0.05)。治疗后,两组基础胃酸分泌量(BAO)、最大胃酸分泌量(MAO)和高峰胃酸分泌量(PAO)均下降,且研究组BAO、MAO和PAO分别为(4.15±1.44)mmol/h、(8.02±2.13)mmol/h和(12.12±3.67)mmol/h,均低于对照组[(5.36±1.98)mmol/h、(10.15±2.99)mmol/h和(15.01±3.59)mmol/h(t=3.388、3.978、3.859,P＜0.05)]。两组不良反应发生率比较,差异无统计学意义(4.26% vs.10.64%,P＞0.05)。结论 富马酸伏诺拉生治疗Hp阳性PU疗效优,可促溃疡愈合,抑胃酸分泌,安全性好。
Abstract
Objective To investigate the clinical effect of fumarate in the treatment of Helicobacter pylori (Hp) positive peptic ulcer (PU). Methods A total of 94 HP-positive PU patients from the gastroenterology outpatient department of the Second Affiliated Hospital of Air Force Military Medical University from May 2022 to April 2024 were selected and randomly divided into control group and study group with 47 cases in each group. The control group was treated with amoxicillin + bismuth colloid pectin + clarithromycin + omeprazole, while the study group was treated with amoxicillin + bismuth colloid pectin + clarithromycin + fumarate Vonorazine orally for 2 weeks. The ulcer healing, Hp eradication, clinical efficacy, gastric acid secretion function and safety of the two groups were compared. Results The ulcer healing rate of the study group was 93.62% (44/47) higher than that of the control group (78.72% (37/47), and the difference was statistically significant (P<0.05). Compared with the control group, the eradication rate of Hp in the study group was higher (87.23% vs. 68.09%, P<0.05). The total effective rate of the two groups was higher in the study group (82.29% vs. 95.74%, χ2=7.029, P<0.05). After treatment, basal gastric acid secretion (BAO), maximum gastric acid secretion (MAO) and peak gastric acid secretion (PAO) decreased in both groups. The BAO, MAO and PAO levels in the study group were (4.15±1.44) mmol/h, (8.02±2.13) mmol/h and (12.12±3.67) mmol/h lower than those in the control group (5.36±1.98) mmol/h, (10.15±2.99) mmol/h and (15.01±3.59) mmol/h (t=3.388, 3.978, 3.859, P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (4.26% vs. 10.64%, P>0.05). Conclusions The treatment effect of fumarate on Hp positive PU is excellent, which is worthy of promotion due to the promotion of ulcer healing, inhibition of gastric acid secretion and its safety.
关键词
消化性溃疡 /
幽门螺杆菌 /
富马酸伏诺拉生 /
胃酸分泌功能
Key words
peptic ulcer /
helicobacter pylori /
Vonorazine fumarate /
gastric acid secretion function
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Laucirica I, García Iglesias P, Calvet X. Peptic ulcer[J]. Med Clin (Barc), 2023, 161(6):260-266.
[2] 郭洪礼,张 涛,梁红亮. 瑞巴派特改良四联疗法用于幽门螺杆菌阳性胃溃疡的临床观察[J]. 中国药房,2021,32(12):1497-1500.
[3] 花 静,陈风娟,陈 莉, 等. 幽门螺杆菌阳性消化性溃疡患者复发风险预警模型构建与验证[J]. 中华保健医学杂志,2024,26(2):190-193.
[4] 崔红霞, 吴美英, 董 一, 等. 艾司奥美拉唑镁肠溶片四联方案治疗老年消化性溃疡出血患者疗效及对Hp清除率、胃肠激素和不良反应的影响[J]. 老年医学与保健,2024,30(2):493-497,518.
[5] St Onge E, Phillips B. Vonoprazan: a new potassium-competitive acid blocker[J]. J Pharm Technol, 2023, 39(3):139-146.
[6] 陈 珑, 焦红梅. 基于富马酸伏诺拉生的幽门螺杆菌根除治疗方案的现状[J]. 中国临床药理学杂志,2022,38(20):2506-2509.
[7] 李军祥, 张 霞. 消化性溃疡的中西医结合诊治[J]. 中国临床医生,2001,29(5):6-8.
[8] 中华医学会. 临床诊疗指南:消化系统疾病分册[M]. 北京:人民卫生出版社, 2005:103.
[9] Kamada T, Satoh K, Itoh T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020[J]. J Gastroenterol, 2021, 56(4):303-322.
[10] Almadi M A, Lu Y, Alali A A, et al. Peptic ulcer disease[J]. Lancet,2024,404(10447):68-81.
[11] 赵 楠. 温脾养胃活血通络汤配合穴位贴敷治疗脾虚血瘀证消化性溃疡效果及对胃酸分泌、创面愈合的影响[J]. 现代中西医结合杂志,2021,30(9):954-958.
[12] Ren J, Jin X, Li J, et al. The global burden of peptic ulcer disease in 204 countries and territories from 1990 to 2019: a systematic analysis for the global burden of disease study 2019[J]. Int J Epidemiol, 2022, 51(5):1666-1676.
[13] 原 宁,宁 萍. 微生态制剂联合奥美拉唑序贯治疗幽门螺杆菌阳性消化性溃疡效果及对患儿丙二醛、转化生长因子β1蛋白水平和肠道菌群的影响[J]. 陕西医学杂志,2021,50(4):472-475.
[14] Katelaris P, Hunt R, Bazzoli F, et al. Helicobacter pylori world gastroenterology organization global guideline[J]. J Clin Gastroenterol, 2023, 57(2):111-126.
[15] Chey W D, Mégraud F, Laine L, et al.Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and Europe: randomized clinical trial[J]. Gastroenterology, 2022, 163(3):608-619.
[16] Qian H S, Li W J, Dang Y N, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of helicobacter pylori infection compared with bismuth-containing quadruple therapy[J]. Am J Gastroenterol, 2023, 118(4):627-634.
[17] Liu L, Nahata M C. Vonoprazan with amoxicillin or amoxicillin and clarithromycin for the tTreatment of helicobacter pylori infection[J]. Ann Pharmacother, 2023, 57(10):1185-1197.
[18] 赵 莹, 赵 晶. 伊托必利联合富马酸伏诺拉生片治疗胃食管反流病的疗效及对患者CGRP、5-HT水平变化的影响[J]. 中国中西医结合消化杂志,2022,30(1):16-20.
[19] Simadibrata D M, Syam A F, Lee Y Y. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(12):2217-2228.
[20] Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole[J]. Br J Clin Pharmacol, 2022, 88(7):3288-3296.
基金
陕西省重点研发计划项目(2023-SF-32)
PDF(958 KB)
